Investigators may have uncovered sex-based disparities in the detection and survival of melanoma in Black patients, according to a recent study published by Steadman et al in the Journal of Surgical Oncology.
2023
Dr Kaczmar on the Future Utility of Cemiplimab With Fianlimab in Advanced Melanoma
John Michael Kaczmar, MD, medical oncologist, associate professor, College of Medicine, Medical University of South Carolina (MUSC), MUSC Health, discusses future implications forthe use of fianlimab (formerly REGN 3767) in combination with cemiplimab-rwlc (Libtayo) for the treatment of patients with advanced melanoma.
Neoadjuvant Daromun Meets Primary End Point of RFS in Melanoma
A trial of intratumoral daromun and surgical resection for the treatment of patients with locally advanced, fully resectable melanoma, showed a clinically meaningful improvement compared with surgery alone.
FDA Approves Adjuvant Nivolumab for Stage IIB/IIC Melanoma
Approval is based on data from Bristol Myers Squibb’s CheckMate – 76K trial.